| 盐酸安罗替尼用于晚期非小细胞肺癌治疗的成本效用分析 |
| |
| 引用本文： | 丁海樱,孔思思,孙娇,许高奇,何超能,黄萍.盐酸安罗替尼用于晚期非小细胞肺癌治疗的成本效用分析[J].卫生经济研究,2020(5):19-22. |
| |
| 作者姓名： | 丁海樱 孔思思 孙娇 许高奇 何超能 黄萍 |
| |
| 作者单位： | 中国科学院肿瘤与基础医学研究所;浙江省人民医院 |
| |
| 基金项目： | 北京医卫健康公益基金会资助“安罗替尼用于非小细胞肺癌三线治疗的经济学研究”(YWJKJJHKYJJ-F2044G)。 |
| |
| 摘 要： | 目的:明确盐酸安罗替尼用于晚期非小细胞肺癌治疗的成本效用。方法:基于三期临床试验ALTER0303数据及医疗成本,建立决策树模型。结果:基础分析结果显示,安罗替尼相比安慰剂的增量成本为52839.72元,增量效用为0.067 QALY,增量成本-效用比为784860.34元/QALY,超出了WTP阈值。结论:在我国目前的经济形势下,安罗替尼相比安慰剂用于晚期非小细胞肺癌患者三线治疗暂不具有经济学优势。
|
| 关 键 词： | 安罗替尼 非小细胞肺癌 成本效用 MARKOV模型 |
Cost-effectiveness Analysis of Anlotinib Hydrochloride for Treatment of Advanced Non-Small Cell Lung Cancer |
| |
| DING Hai-ying,KONG Si-si,SUN Jiao,XU Gao-qi,HE Chao-neng,HUANG Ping.Cost-effectiveness Analysis of Anlotinib Hydrochloride for Treatment of Advanced Non-Small Cell Lung Cancer[J].Health Economics Research,2020(5):19-22. |
| |
| Authors: | DING Hai-ying KONG Si-si SUN Jiao XU Gao-qi HE Chao-neng HUANG Ping |
| |
| Institution: | (Institute of Cancer and Basic Medicine(ICBM),Chinese Academy of Sciences,Cancer Hospital of the University of Chinese Academy of Sciences,Zhejiang Cancer Hospital,Hangzhou Zhejiang 310022,China;不详) |
| |
| Abstract: | Objective To clarify the cost-effectiveness of anlotinib hydrochloride for the treatment of advanced non-small cell lung cancer.Methods A decision tree model was established by the data and medical costs of phase III clinical trial ALTER0303.Results The analysis results showed that the incremental cost of anlotinib compared to placebo was 52839.72 yuan,the incremental utility was 0.067 QALY,and the incremental cost-utility ratio was 784860.34 yuan/QALY,which exceeded the WTP threshold value.Conclusion In the current economic situation in China,anlotinib has no economic advantages compared to placebo for third-line treatment of patients with advanced non-small cell lung cancer. |
| |
| Keywords: | anlotinib non-small cell lung cancer cost effectiveness Markov model |
| 本文献已被 维普 等数据库收录！ |
|
